Sandra Demaria

This account is not active. You can find me @sandrademarialab.bsky.social

¿Cómo avanzarán las inmunoterapias contra el cáncer de mama en los próximos 1⃣0⃣ años? 🔬 @deVisserKarin, @DemariaLab_WCM y @Casanova_Acebes nos traen algunas claves de lo hablado hace unos días en el @CNIOStopCancer-#CaixaResearch Frontiers Meeting.👇 saludentuvida.com/cancer-3/tres-…

Join the SITC Run Club for the 2025 AACR Runners for Research 5K Run/Walk in support of Cancer Research! do.nr/49dr11dl via @DonorDrive @gulleyj1 @JennGuerriero

@FaltasLab @CD_AACR @Nature Congratulations on the beautiful work!

Thank you @CD_AACR news for highlighting our recent paper in @Nature aacrjournals.org/cdnews/news/18… nature.com/articles/s4158…

Happy to be recognized by @Clarivate as a 2024 Highly Cited Researcher who has demonstrated significant influence in their field! #HighlyCited2024 clarivate.com/highly-cited-r…

➡️Join us October 11th at the JBL Symposium to hear from leaders in radiation oncology and AI in medicine including @HugoAerts (@harvardmed) @DrRebeccaHowel1 (@MDAndersonNews) @DemariaLab_WCM (@WeillCornell) & @HenningWillers (@MGHCancerCenter)! Info: hsph.harvard.edu/jbl-center/jbl…

September @sitcancer #JITC Reading List by Section Editor Sandra Demaria @DemariaLab_WCM @WeillCornell selection #4: FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment by @RockefellerUniv and @ChilesResearch bit.ly/3MRuLoU

Jalal Ahmed presented exciting insights into enhancing CAR T cell therapy in solid tumors in the last talk of this "Novel Approaches" session. His talk focused on how radiotherapy (RT) can improve the effectiveness of CAR T cells in solid tumors.

🗺 To finish this second day of the Immunorad conference, Brian D. Brown presented exciting research on how tumor microenvironment (TME) composition impacts immunotherapy (IO) success.

Dr. Sierra McDonald presented complementary findings from the P-RAD clinical trial and a genetically engineered TNBC mouse model:

⭐ Exciting takeaways from Anguraj Sadanandam, Ph.D.'s talk on AI and single-cell data analysis. He began by discussing the challenges of data-driven algorithms, emphasizing that cancer evolution is multifactorial and requires diverse data inputs.

Timothy Chan kicked off the "Cancer Immunogenomics and Radiation Therapy" session with a detailed talk emphasizing the need for biomarker identification to improve the efficacy of RT/IO combinations.

⌚️To finish this session, Sean Pitroda presented extensive research on “Immunogenomic Responses to Combination SBRT and Immune Checkpoint Blockade in Metastatic NSCLC.” , from a recently published work originally from COSINR randomized phase I trial.

Exciting updates from Gaorav Gupta on the P-RAD trial—the first randomized study comparing aPD-1 alone vs. aPD-1 + RT in early-stage, LN metastatic, TNBC, and high-risk HR-HER2- breast cancer:

Great insights from Dr. Kristina Young’s talk on targeting TGF-β in rectal cancer, showing that TGF-β directly impact CD8+ T-cells anti-tumor efficacy

🌟 Exciting Insights from Alan Melcher's talk on T Cell Dynamics and Radiotherapy in Rectal Cancer! 🌟 During his presentation, Prof. Melcher highlighted how a strong immune response to radiotherapy mimics viral infection.

⭐️Kicking off the second day of ImunoRad, Anne-Gaëlle Goubet presented an exciting talk on leveraging Flash Radiotherapy for immune engagement and tumor control.

Dr. Ben Chetrit stressed the need for developing innate immune strategies, particularly targeting Notch4 to reverse macrophage-related immunosuppression.

"Radiation Therapy-Induced Modulation of the Tumor Immune Microenvironment" kicked off with insights from James Welsh on novel strategies to tackle checkpoint resistance.

📷 Gut-Immune Axis: Healthy gut microbiome dysbiosis can enhance the immune system's ability to fight cancer cells 📷Low-dose #radiation: When combined with specific gut bacteria, can boost the response to immunotherapy and may drive the #abscopal effect. Prospective study inc